ATE402956T1 - Neue, mhc klasse ii assoziierte peptide - Google Patents

Neue, mhc klasse ii assoziierte peptide

Info

Publication number
ATE402956T1
ATE402956T1 AT03748078T AT03748078T ATE402956T1 AT E402956 T1 ATE402956 T1 AT E402956T1 AT 03748078 T AT03748078 T AT 03748078T AT 03748078 T AT03748078 T AT 03748078T AT E402956 T1 ATE402956 T1 AT E402956T1
Authority
AT
Austria
Prior art keywords
mhc class
antigenic peptides
associated peptides
tumors
present
Prior art date
Application number
AT03748078T
Other languages
English (en)
Inventor
Harald Kropshofer
Till Roehn
Anne Vogt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE402956T1 publication Critical patent/ATE402956T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03748078T 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide ATE402956T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022224 2002-10-02

Publications (1)

Publication Number Publication Date
ATE402956T1 true ATE402956T1 (de) 2008-08-15

Family

ID=32049974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748078T ATE402956T1 (de) 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide

Country Status (9)

Country Link
US (2) US20050202009A1 (de)
EP (1) EP1549673B1 (de)
JP (1) JP2006518982A (de)
CN (3) CN101185754A (de)
AT (1) ATE402956T1 (de)
AU (1) AU2003267401A1 (de)
CA (1) CA2498854A1 (de)
DE (1) DE60322559D1 (de)
WO (1) WO2004031230A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916340B2 (en) 2006-01-06 2014-12-23 The John Hopkins University Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay
US8569244B2 (en) * 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
US8148090B2 (en) 2007-10-18 2012-04-03 Medical Proteoscope Co., Ltd. Method for prediction of postoperative prognosis and diagnosis kit
US9279011B2 (en) * 2009-05-05 2016-03-08 The Johns Hopkins University Phosphopeptides as melanoma vaccines
WO2011011688A2 (en) * 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
JP2017528430A (ja) * 2014-07-17 2017-09-28 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 免疫に基づく療法のための、免疫原性mhcクラスiiペプチドの同定
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
EP3419656A4 (de) * 2016-02-22 2019-10-30 Oceanside Biotechnology Neoantigenzusammensetzungen und verfahren zur verwendung davon in der immunonkotherapie
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
CN111499716A (zh) 2017-04-10 2020-08-07 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
WO2019243461A1 (en) * 2018-06-19 2019-12-26 Fondazione Telethon Production of engineered dendritic cells and uses thereof
BR112021023173A2 (pt) 2019-07-10 2022-01-04 Chugai Pharmaceutical Co Ltd Moléculas de ligação à claudin-6 e usos das mesmas
CN112618712A (zh) * 2021-01-21 2021-04-09 武汉轻工大学 一种含波形蛋白的佐剂及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
CN101260154A (zh) 2008-09-10
CN101185754A (zh) 2008-05-28
JP2006518982A (ja) 2006-08-24
EP1549673A2 (de) 2005-07-06
CN1688602A (zh) 2005-10-26
US20050202009A1 (en) 2005-09-15
WO2004031230A3 (en) 2005-01-13
EP1549673B1 (de) 2008-07-30
AU2003267401A1 (en) 2004-04-23
CA2498854A1 (en) 2004-04-15
CN100347191C (zh) 2007-11-07
US20070073042A1 (en) 2007-03-29
DE60322559D1 (de) 2008-09-11
WO2004031230A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
DE60322559D1 (de) Neue, mhc klasse ii assoziierte peptide
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
DE69531167D1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen-karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
EA202192991A1 (ru) Новые раковые антигены и сопутствующие способы
DE60237588D1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties